건선 치료용 인터루킨 억제제 시장 : 세계 예측(2026-2032년)

The Interleukin Inhibitors for Psoriasis Market is projected to grow by USD 8.02 billion at a CAGR of 9.86% by 2032.

Interleukin Inhibitors Are Reshaping Psoriasis Care

Interleukin inhibitors have become an important component of systemic psoriasis treatment, particularly for patients with moderate-to-severe plaque psoriasis. Their development reflects a shift toward targeted immune modulation, with therapies designed to interrupt specific cytokine pathways associated with inflammation rather than suppressing immune activity broadly. Clinical decision-making increasingly considers skin clearance, durability of response, safety, comorbidities, patient preference, administration frequency, and access to specialist care.

Targeted Immunology Is Changing Treatment Pathways

The therapeutic landscape is moving from conventional systemic treatment toward biologically targeted options supported by pathway-specific evidence. Interleukin-17, interleukin-23, and related mechanisms have differentiated treatment choices by balancing rapid response, sustained control, dosing convenience, and safety considerations. This transition is also encouraging more structured use of treatment guidelines, shared decision-making, longitudinal monitoring, and integrated management of psoriatic arthritis and other associated conditions.

Artificial Intelligence Supports Evidence, Diagnosis, and Care Coordination

Artificial intelligence is contributing to psoriasis care through image-assisted assessment, patient stratification, clinical-trial recruitment, pharmacovigilance, and analysis of treatment-response patterns. These applications may help clinicians standardize severity evaluation and identify patients who require escalation or closer monitoring. However, effective adoption depends on representative datasets, transparent validation, privacy safeguards, clinician oversight, and clear separation between decision support and autonomous prescribing.

Regional Differences Reflect Access, Regulation, and Specialist Capacity

North America generally benefits from established biologic treatment pathways, specialist networks, and broad clinical experience, while reimbursement rules and prior authorization can influence access. Europe combines mature guideline systems with country-level differences in health-technology assessment, procurement, and eligibility criteria. Asia-Pacific presents substantial variation in regulatory adoption, specialist availability, and affordability, alongside expanding dermatology capacity. Latin America faces uneven reimbursement and access, with larger urban centers often better served than remote areas. The Middle East is developing specialized care infrastructure but differs considerably by national coverage systems. Africa continues to encounter constraints involving diagnosis, biologic availability, cold-chain logistics, and specialist density, making implementation and affordability central considerations.

Multilateral Groups Reveal Different Policy and Access Priorities

ASEAN markets share opportunities for regional learning but differ in regulatory maturity, reimbursement, and healthcare infrastructure. BRICS members represent diverse clinical systems, manufacturing capabilities, and affordability priorities, making local evidence and access models especially relevant. European Union countries operate within coordinated regulatory structures while retaining national reimbursement decisions. G7 health systems generally have extensive specialist capacity and sophisticated evidence requirements, although administrative barriers remain important. GCC countries often combine well-resourced urban healthcare systems with centralized procurement and a focus on specialist services. NATO members span varied health systems, but common attention to resilience, supply continuity, and preparedness can influence biologic distribution and care delivery.

Country Context Determines Adoption and Patient Access

Australia and Canada combine specialist-led care with public reimbursement frameworks that can impose eligibility or administrative requirements. Brazil, Mexico, India, China, and Russia show substantial internal variation in affordability, urban access, regulatory implementation, and local production or procurement priorities. Japan and South Korea have advanced specialist capabilities and structured reimbursement environments, with local clinical practice influencing treatment selection. France, Germany, Italy, Spain, and the United Kingdom have strong dermatology networks and established guidance, but differ in assessment procedures, tendering, prescribing controls, and regional implementation. Across the United States, broad therapeutic choice is balanced by payer authorization, insurance design, and disparities in specialist access.

Leaders Should Link Clinical Value With Access and Evidence

Industry leaders should prioritize robust comparative evidence covering durable skin clearance, quality of life, psoriatic arthritis relevance, safety, adherence, and real-world persistence. Access strategies should be tailored to national reimbursement structures and supported by transparent eligibility tools, patient assistance where permitted, and reliable distribution. Organizations should invest in clinician education, diagnostic capacity, and shared decision-making rather than relying solely on product differentiation. AI initiatives should use validated dermatology datasets, explainable outputs, strong governance, and continuous monitoring for bias. Supply-chain resilience, pharmacovigilance, and responsible evidence communication should remain core operating priorities.

Methodology Combines Verified Clinical, Regulatory, and Health-System Evidence

This executive summary uses a structured review of publicly available clinical, regulatory, guideline, and health-system evidence relevant to interleukin inhibitors for psoriasis. The assessment compares treatment mechanisms, care pathways, access conditions, monitoring considerations, and implementation barriers across the specified regions, groups, and countries. Evidence interpretation emphasizes documented findings and avoids unsupported commercial projections. Regional and country observations are framed as contextual differences rather than quantitative market claims, with attention to the limitations created by heterogeneous reimbursement systems, reporting practices, and clinical infrastructure.

Sustainable Progress Depends on Patient-Centered Implementation

Interleukin inhibitors have strengthened the therapeutic toolkit for psoriasis by aligning treatment with increasingly precise understanding of inflammatory pathways. Their practical impact will depend not only on clinical efficacy, but also on affordability, diagnosis, specialist capacity, reimbursement, safety monitoring, and continuity of supply. Leaders that combine rigorous evidence, responsible innovation, equitable access, and patient-centered care will be better positioned to translate advances in immunology into durable improvements in psoriasis outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Interleukin Inhibitors for Psoriasis Market, by Drug Class

• 7.1. Introduction
• 7.2. Interleukin 12/23 Inhibitors
• 7.3. Interleukin 17 Inhibitors
  • 7.3.1. Brodalumab
  • 7.3.2. Ixekizumab
  • 7.3.3. Secukinumab
• 7.4. Interleukin 23 Inhibitors
  • 7.4.1. Guselkumab
  • 7.4.2. Risankizumab
  • 7.4.3. Tildrakizumab

8. Interleukin Inhibitors for Psoriasis Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Subcutaneous

9. Interleukin Inhibitors for Psoriasis Market, by Treatment Line

• 9.1. Introduction
• 9.2. First Line Treatment
• 9.3. Refractory Treatment
• 9.4. Second Line Treatment

10. Interleukin Inhibitors for Psoriasis Market, by Patient Severity

• 10.1. Introduction
• 10.2. Moderate Psoriasis
• 10.3. Severe Psoriasis

11. Interleukin Inhibitors for Psoriasis Market, by End User

• 11.1. Introduction
• 11.2. Dermatology Clinics
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Interleukin Inhibitors for Psoriasis Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacy
• 12.3. Online Pharmacy
• 12.4. Retail Pharmacy

13. Interleukin Inhibitors for Psoriasis Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Interleukin Inhibitors for Psoriasis Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Interleukin Inhibitors for Psoriasis Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. AstraZeneca PLC
• 17.4. Bausch Health Companies Inc.
• 17.5. Boehringer Ingelheim International GmbH
• 17.6. Bristol-Myers Squibb Company
• 17.7. Eli Lilly and Company
• 17.8. F. Hoffmann-La Roche Ltd.
• 17.9. GlaxoSmithKline plc
• 17.10. Janssen Biotech, Inc.
• 17.11. LEO Pharma A/S
• 17.12. Merck & Co., Inc.
• 17.13. Novartis AG
• 17.14. Pfizer Inc.
• 17.15. Regeneron Pharmaceuticals, Inc.
• 17.16. Samsung Bioepis Co., Ltd.
• 17.17. Sanofi
• 17.18. Sun Pharmaceutical Industries Limited
• 17.19. Takeda Pharmaceutical Company Limited
• 17.20. UCB S.A.

18. Key Experts